In the I-SPY 2 trial, MK-2206 (an allosteric inhibitor) combined with standard neoadjuvant chemotherapy contributed to higher pathologic complete response rates in human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-negative early-stage breast cancer. This evidence concerns the gene NR4A1 and breast cancer.